Compare BXBL & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXBL | DRTS |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2023 | 2021 |
| Metric | BXBL | DRTS |
|---|---|---|
| Price | $4.37 | $14.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 172.9K | ★ 608.8K |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $3.43 |
| 52 Week High | $5.42 | $15.17 |
| Indicator | BXBL | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 49.16 | 54.28 |
| Support Level | $3.99 | $13.65 |
| Resistance Level | $4.56 | $14.93 |
| Average True Range (ATR) | 0.34 | 0.58 |
| MACD | 0.04 | -0.08 |
| Stochastic Oscillator | 71.34 | 50.33 |
BOXABL Inc is engaged in building construction using modern manufacturing processes to create residential and commercial buildings that can be completed in less time and at lower cost than traditional construction. The Company has developed a building system using manufacturing processes and existing technologies and processes developed by the automotive industry. Its products include the Casita and other building solutions using patented folding and shipping technology to transport buildings on existing roadways across large geographic areas.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.